stockrow
Friday 6 November 2026
Export LQDA’s income statement to Excel — free account
Liquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
44.56
0.07
+0.16%
Follow LQDA
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 5 | 4 |
+8 more TTM periods Free account |
| 131.82% | 28.18% | (111.05%) | (184.04%) | ||
| 35.57% | 7.09% | (24.69%) | (46.13%) | ||
ROIC |
121.05% | 44.72% | (70.71%) | (117.51%) | |
Return on Tangible Assets |
48.98% | 10.93% | (46.11%) | (90.71%) | |
Average Days of Receivables |
87.90 | 93.96 | 124.71 | 189.62 | |
Free Cash Flow per Share |
1.70 | 0.47 | (0.47) | (1.21) | |
Free Cash Flow |
150.69 | 41.15 | (40.02) | (104.32) | |
Capital Expenditures |
(17.01) | (6.84) | (4.34) | (3.58) | |
| Other line items | |||||
Cash ROIC |
22.99% | 8.08% | (9.38%) | (28.04%) | |
Accounts Receivable Turnover |
7.61 | 7.64 | 5.57 | 3.45 | |
Accounts Payable Turnover |
2.79 | 2.40 | 3.17 | 1.81 | |
Inventory Turnover |
1.58 | 1.58 | 1.10 | 0.61 | |
Average Days of Payables |
138.36 | 170.00 | 101.38 | 291.33 | |
Days of Inventory on Hand |
392.64 | 441.31 | 656.07 | 1,187.50 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12.43% | 15.58% | 24.81% | 56.07% | |
Selling, General and Administrative Expense of Revenue |
42.73% | 60.42% | 99.28% | 188.02% | |
Share Based Compensation of Revenue |
7.69% | 10.85% | 18.62% | 39.43% | |
Interest Coverage |
6.33 | 1.75 | (2.13) | (4.93) | |
Operating CF/Net income |
1.21 | 2.15 | 0.52 | 0.83 | |
Depreciation/Fixed assets |
0.05 | 0.08 | 0.13 | 0.16 | |
Capex/Depreciation |
(10.05) | (4.34) | (2.84) | (2.07) | |
Revenue per Share |
5.07 | 3.27 | 1.84 | 0.80 | |
Operating CF per Share |
1.89 | 0.55 | (0.41) | (1.17) | |
Capex per Share |
(0.19) | (0.08) | (0.05) | (0.04) | |
Capex to Sales |
0.04 | 0.02 | 0.03 | 0.05 |
Columns are period end dates · fundamentals updated 26 Oct 2026